Table 1.
Baseline demographics and clinical data of patients and HC.
| Discovery cohort |
Validation cohort |
|||
|---|---|---|---|---|
| MS (n = 35) | HC (n = 25) | MS (n = 20) | HC (n = 20) | |
| Age (mean ± SD) | 40.45 ± 10.6 | 40.73 ± 10.2 | 33.35 ± 10.74 | 33.6 ± 10.97 |
| Age range | 17–57 | 26–58 | 21–55 | 22–57 |
| P value | 0.153 (ns) | 0.942 (ns) | ||
| Male | 11 | 11 | 5 | 5 |
| Female | 24 | 14 | 15 | 15 |
| MS course | RRMS (n = 35) | – | RRMS (n = 20) | – |
| Disease duration in year from CIS (mean ± SEM) | 8.79 ± 1.3 | – | 4.18 ± 1.85 | – |
| Disease duration in year from CD-MS (mean ± SEM) | 5.99 ± 0.99 | – | 0.36 ± 0.16 | – |
| EDSS (mean ± SEM) | N/A | – | 0.97 ± 0.21 | – |
ns, not significant; RRMS, relapsing-remitting MS, CIS, clinically isolated syndrome; CD-MS, clinically definite MS; EDSS; expanded disability status score; N/A, not available.
Disease duration was calculated from the CIS or CDMS date to the sampling date. EDSS in the discovery cohort were only available for 4 patients. EDSS in the validation cohort were available for 19 out of 20 patients.